Ieq Capital LLC Raises Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Ieq Capital LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,090.6% during the fourth quarter, HoldingsChannel reports. The firm owned 27,206 shares of the company’s stock after purchasing an additional 24,921 shares during the period. Ieq Capital LLC’s holdings in Medpace were worth $9,039,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. R Squared Ltd purchased a new position in shares of Medpace in the fourth quarter worth about $30,000. Stone House Investment Management LLC acquired a new stake in Medpace in the 3rd quarter valued at about $33,000. Ashton Thomas Securities LLC acquired a new stake in Medpace in the 3rd quarter valued at about $37,000. Capital Performance Advisors LLP purchased a new position in Medpace in the 3rd quarter worth approximately $46,000. Finally, True Wealth Design LLC boosted its holdings in shares of Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Stock Performance

MEDP stock opened at $344.85 on Friday. The firm has a market cap of $10.51 billion, a PE ratio of 27.30, a PEG ratio of 3.77 and a beta of 1.36. Medpace Holdings, Inc. has a one year low of $302.01 and a one year high of $459.77. The firm’s 50 day moving average price is $343.28 and its 200-day moving average price is $347.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.